Clinical Trial Update: DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI [NA]

View source ↗

Summary

This document provides an update on the DEFLECT III trial evaluating the TriGuard HDH Embolic Deflection Device during transcatheter aortic valve implantation; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Stenosis

Drugs mentioned

• TriGuard HDH Embolic Deflection Device

Snippet

Sponsor: Keystone Heart | Conditions: Aortic Valve Stenosis | NA | Status: COMPLETED